Expected Drop In COVID-19 Vaccine Sales Hits Beximco’s Bottom Line
Subsidiary Entities Collectively Profitable For First Time Following Synovia Acquisition
The absence of any income from distributing AstraZeneca’s COVID-19 vaccine led to Beximco’s pre-tax profit dropping by 13% in the first six months of its financial year ending in June 2023. However, profits after tax actually rose slightly when discounting last year’s COVID-19 vaccine impact.
You may also be interested in...
Rising inflation and the depreciation of the Bangladeshi taka have taken their toll on Beximco’s profits even as revenue has continued to rise at the firm.
Following a year of impressive business developments, economic developments such as a depreciating local currency threaten to knock Beximco off-course.
Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.